KIDS SHOULD GROW STRONGER.

Their nearsightedness shouldn’t.

Slowing the Progression of Nearsightedness Starts Here

MiSight®1 day contact lenses are the first and ONLY soft contact lenses that are FDA approved* to slow the progression of myopia in children 8-12 years of age at initiation of treatment¹.

What is Myopia?

Myopia = Nearsightedness

Whether or not your child complains of not being able to see objects at a distance—such as the board at the front of their classroom— they might have a condition called myopia. It’s more commonly known, though, as nearsightedness.

The eyes of a child with myopia become longer over time, which causes distant objects to appear blurry. And, if it’s not addressed, myopia often worsens as your child gets older.

What Does Myopia Look Like?

If you’re wondering what myopia looks like through your child’s eyes, find out by using our Myopia Simulator

See the world through your child’s eyes. Experience the Myopia Simulator.

Start Now

Start managing your child’s myopia today

  1. The First and Only. MiSight® 1 day is the first and only FDA-approved* soft contact lens to slow the progression of myopia in children aged 8 -12 at the initiation of treatment1†.
  2. Clinically Proven and Safe. Over a 3-year period, slowed myopia progression 59% on average, reduced eye lengthening by 52% on average1†§, and 41% of eyes had no progression1†¶. Over a 6-year period, children wearing MiSight 1 day progressed less than 1.00D on average.
  3. Parent-Approved. 90% of parents whose children wore MiSight® 1 day contact lenses reported that their children were happy wearing MiSight® 1 day lenses3|.
  4. Child Friendly. After using MiSight® 1 day contact lenses for three years, 90% of children still strongly preferred them over their glasses4.
ManageMyopia

Brilliant Futures™ Myopia Management Program

Managing your child’s myopia—both today and in the future—requires more than just vision correction. The Brilliant Futures™ Myopia Management Program with MiSight® 1 day contact lenses provides you with:

Comprehensive support
Knowledge
Tools

And confidence you need throughout your child’s clinical treatment to optimize clinical outcomes today and in the future.

At CooperVision, we have a history of developing proven solutions for many of the toughest vision challenges—including childhood myopia. And, today, we’re leading the way in helping children like yours see better today and in the future.

Our innovative technologies and products—including MiSight® 1 day contact lenses—are making a difference. And our Brilliant Futures™ Myopia Management Program is just one more step we’re taking in setting a new standard of care for treating myopia in children.

Through the support provided by CooperVision’s Brilliant Futures™ Myopia Management Program, you can help your child live their best and brightest future. Ask your Brilliant Futures™ Myopia Management Program-certified eye care doctor about how you can get started.

The journey toward a brighter future starts today.

ManageMyopia

FDA-approved

MiSight® 1 day contact lenses are FDA-approved* to slow the progression of myopia in children 8 to 12 years of age at initiation of treatment1†. That means that they’ve been comprehensively tested over an extended period and have met all of the safety criteria required by the Food and Drug Administration (FDA).

Clinical Data

The testing of MiSight® 1 day lenses consisted of a three-year clinical study in children 8-12 years old at the time they began treatment for myopia. Half of these children wore MiSight® 1 day contact lenses and the other half wore traditional 1 day soft contact lenses. This way, we could see if MiSight® 1 day really made a difference. And they did. The progression of myopia slowed in 41% of children who wore MiSight® 1 day contact lenses as compared to those who didn’t1†.

Request for more information

*By submitting this form, you grant CooperVision, Inc. permission to add your contact information to our database to send you information and communications related to our products and services. The use of personal contact information will be treated in accordance with CooperVision’s Privacy Policy and in accordance to with the California Consumer Privacy Act of 2018 (CCPA)

For consumer care call: 1-855-526-6737
*Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

†Compared to a single vision 1 day lens over a 3 year period.

§Children aged 8-12 at the initiation of treatment.

¶No clinically meaningful change in refractive error -0.25D or less from baseline.

|Overall experience as defined as children's comfort, vision, lens handling, and freedom from spectacles. Children aged 8-15 years.

References:

¹Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. Optom Vis Sci. 2019; 96(8):556-567.
²Chamberlain P, Arumugam B, Jones D et al. Myopia Progression in Children wearing Dual-Focus Contact Lenses: 6-year findings. Optom Vis Sci 2020;97(E-abstract): 200038.
³CVI data on file 2018. 3- year study report.
⁴Sulley A et al. Wearer experience and subjective responses with dual focus compared to spherical, single vision soft contact lenses in children during a 3-year clinical trial. AAO 2019 Poster Presentation.